Vliyanie Tselleksa na dinamiku rechevykh rasstroystv v ostrom periode ishemicheskogo insul'ta

The article describes the results of a double-blind, placebo-controlled, randomized, multi-center clinical trial of the efficacy of Cellex (protein-peptide complex from porcine fetal brain tissue) in the treatment of patients with acute ischemic stroke. The study involved 480 patients who received either Cellex or placebo with standard combination therapy. It was found that the use of Cellex in acute ischemic stroke resulted in a significant decrease in NIH Stroke Scale (NIHSS) in the area of speech disorders, restoration of speech on the scale «speech questionnaire»: increase in score by more than 15% compared with the control group, and the 3-fold increase in patients with serious speech disorders. Therefore, the comparative assessment of the score dynamics using international clinical scales has led to the conclusion of sufficiently high efficacy of Cellex in early periods after acute cerebral infarction. Cellex application results in a significant increase in the recovery of lost speech functions in all groups of stroke patients, especially in moderate and severe stroke.

ischemic stroke, cerebral infarction, speech disorder, Cellex